ReVision Implant secures €4M to advance vision restoration technology

ReVision Implant, a Belgian neurotechnology
company developing a cortical visual prosthesis for people with severe
blindness, has secured €4 million in an oversubscribed funding round backed by
private investors.

The round included participation from existing
investors as well as new backers, including European business leaders and
medtech operators.

The funding builds on ReVision Implant’s existing
support from public programmes, including several highly selective European
Innovation Council grants such as the €2.4 million FlairVision project. The
company is also supported by the Plug and Play and imec.istart incubators.

ReVision Implant is developing a brain-computer
interface designed to restore functional vision in patients who cannot benefit
from retinal or optic nerve-based therapies. By interfacing directly with the
brain’s visual cortex, the system aims to bypass damage to the eye and optic
nerve and enable patients to perceive and interpret visual information.

The company began building its own cleanroom
infrastructure several months ago as part of preparations for future clinical
trials and greater control over manufacturing and quality processes.

According to Frederik Ceyssens, CEO of ReVision
Implant, the funding represents a key milestone as the company moves from
development into the next phase of clinical and operational expansion.

We are investing in our own cleanroom
environment to bring important manufacturing steps in-house, while expanding
our team and advancing our regulatory compliance and clinical programme over
the coming years. At the same time, we are continuing product development and
strengthening our collaborations with other medtech companies as we move closer
to bringing our technology to patients.

The company’s progress comes amid broader
advances in neurotechnology and brain-computer interfaces, with growing
interest in devices designed to help address conditions including blindness,
paralysis, amputations, aphasia, and locked-in syndrome.

With the new funding secured, ReVision Implant is
preparing for the next stage of clinical development and operational scale-up.